

Serial No.: 10/698,121

Confirmation No.: 8958

Filed: October 31, 2003

For: INDUCIBLE LIGAND FOR $\alpha 1\beta 1$ INTEGRIN AND USES

Amendments to the Claims

This listing of claims replaces all prior versions, and listings, of claims in the above-identified application:

1-5. (Canceled)

6. (Currently amended) The method of claim [[1]] 44 wherein the antibody blocks the interaction of $\alpha 1\beta 1$ integrin on peripheral blood monocytes with Collagen XIII on vascular endothelium of chronically inflamed tissues.

7. (Previously Presented) A method for treating a subject having an inflammatory disease or other condition where integrin $\alpha 1\beta 1$ -positive interstitial monocyte accumulation is observed, the method comprising administering to the subject an antibody to Collagen XIII that disrupts the interaction between Collagen XIII and $\alpha 1\beta 1$ integrin.

8. (Previously Presented) The method of claim 7 wherein the antibody to Collagen XIII blocks binding of Collagen XIII and $\alpha 1\beta 1$ integrin.

9. (Canceled)

10. (Previously Presented) The method of claim 7 wherein the antibody is a monoclonal antibody.

11. (Previously Presented) The method of claim 7 wherein the inflammatory disease or other condition is renal fibrosis or crescentic glomerulonephritis.

Serial No.: 10/698,121

Confirmation No.: 8958

Filed: October 31, 2003

For: INDUCIBLE LIGAND FOR $\alpha 1\beta 1$ INTEGRIN AND USES

12. (Previously Presented) The method of claim 7 wherein the antibody blocks the interaction of $\alpha 1\beta 1$ integrin on peripheral blood monocytes with Collagen XIII on vascular endothelium of chronically inflamed tissues.

13. (Previously Presented) A method of reducing selective efflux of integrin $\alpha 1\beta 1$ -positive monocytes into the interstitium of chronically inflamed tissues, the method comprising contacting the $\alpha 1\beta 1$ integrin on peripheral blood monocytes with an antibody to Collagen XIII that interferes with the interaction between Collagen XIII and $\alpha 1\beta 1$ integrin.

14. (Canceled)

15. (Previously Presented) The method of claim 13 wherein the antibody blocks the interaction of $\alpha 1\beta 1$ integrin on peripheral blood monocytes with Collagen XIII on the cell surface of the vascular/capillary endothelial cells of inflamed tissues.

16. (Canceled)

17. (Previously Presented) A method of reducing the rate of monocyte efflux into the interstitial space of chronically inflamed tissues, the method comprising contacting the tissue with an antibody to Collagen XIII wherein the antibody blocks Collagen XIII from binding with $\alpha 1\beta 1$ integrin.

18-20. (Canceled)

21. (Previously Presented) The method of claim 17 wherein the antibody is a monoclonal antibody.

22. (Canceled)

Serial No.: 10/698,121

Confirmation No.: 8958

Filed: October 31, 2003

For: INDUCIBLE LIGAND FOR $\alpha 1\beta 1$ INTEGRIN AND USES

23. (Previously Presented) A method of blocking the interaction of $\alpha 1\beta 1$ integrin on peripheral blood monocytes with Collagen XIII on vascular endothelium of chronically inflamed tissues, the method comprising contacting the monocytes, the vascular endothelium, or both with an antibody to Collagen XIII.

24. (Canceled)

25. (Previously Presented) The method of claim 23 wherein the antibody is a monoclonal antibody.

26-27. (Canceled)

28. (Previously Presented) The method of claim 7 wherein the antibody inhibits the binding of fluorochrome-conjugated purified $\alpha 1\beta 1$ integrin to MCP-1-treated vascular endothelial cells in culture.

29-42. (Canceled)

43. (Currently Amended) A method of treating a patient having a ~~kidney disease~~ chronically inflamed kidneys associated with an accumulation of $\alpha 1\beta 1$ integrin positive monocytes in the interstitium, the method comprising administering to the patient an antibody to Collagen XIII, wherein the antibody reduces the rate of efflux of $\alpha 1\beta 1$ integrin positive monocytes into the renal interstitium.

44. (Currently Amended) A method of treating a patient having a ~~progressive~~ renal fibrosis, the method comprising administering to the patient an antibody to Collagen XIII, wherein the antibody prevents the binding of Collagen XIII to $\alpha 1\beta 1$ integrin positive monocytes.

45. (Previously Presented) The method of claim 13 wherein the antibody is a monoclonal antibody.

46. (Previously Presented) The method of claim 17 wherein the antibody blocks the interaction of $\alpha 1\beta 1$ integrin on peripheral blood monocytes with Collagen XIII on vascular endothelium of chronically inflamed tissues.

47. (Previously Presented) The method of claim 23 wherein the antibody blocks the interaction of $\alpha 1\beta 1$ integrin on peripheral blood monocytes with Collagen XIII on vascular endothelium of chronically inflamed tissues.

48. (Previously Presented) The method of claim 13 wherein the antibody inhibits binding of fluorochrome-conjugated purified $\alpha 1\beta 1$ integrin to MCP-1 treated primary endothelial cells in culture.

49. (Previously Presented) The method of claim 17 wherein the antibody inhibits binding of fluorochrome-conjugated purified $\alpha 1\beta 1$ integrin to MCP-1 treated primary endothelial cells in culture.

50. (Previously Presented) The method of claim 23 wherein the antibody inhibits binding of fluorochrome-conjugated purified $\alpha 1\beta 1$ integrin to MCP-1 treated primary endothelial cells in culture.

51. (Previously Presented) The method of claim 43 wherein the antibody inhibits binding of fluorochrome-conjugated purified $\alpha 1\beta 1$ integrin to MCP-1 treated primary endothelial cells in culture.

Serial No.: 10/698,121

Confirmation No.: 8958

Filed: October 31, 2003

For: INDUCIBLE LIGAND FOR $\alpha 1\beta 1$ INTEGRIN AND USES

52. (Previously Presented) The method of claim 44 wherein the antibody inhibits binding of fluorochrome-conjugated purified $\alpha 1\beta 1$ integrin to MCP-1 treated primary endothelial cells in culture.

53. (Canceled)

54. (Previously Presented) The method of claim 7 wherein the antibody binds to a peptide fragment of Collagen XIII, the peptide fragment having SEQ ID NO:1.

55. (Previously Presented) The method of claim 13 wherein the antibody binds to a peptide fragment of Collagen XIII, the peptide fragment having SEQ ID NO:1.

56. (Previously Presented) The method of claim 17 wherein the antibody binds to a peptide fragment of Collagen XIII, the peptide fragment having SEQ ID NO:1.

57. (Previously Presented) The method of claim 23 wherein the antibody binds to a peptide fragment of Collagen XIII, the peptide fragment having SEQ ID NO:1.

58. (Previously Presented) The method of claim 43 wherein the antibody binds to a peptide fragment of Collagen XIII, the peptide fragment having SEQ ID NO:1.

59. (Previously Presented) The method of claim 44 wherein the antibody binds to a peptide fragment of Collagen XIII, the peptide fragment having SEQ ID NO:1.

60. (Canceled)

61. (Withdrawn) The method of claim 7 wherein the antibody binds to a peptide fragment of Collagen XIII, the peptide fragment having SEQ ID NO:2.

62. (Withdrawn) The method of claim 13 wherein the antibody binds to a peptide fragment of Collagen XIII, the peptide fragment having SEQ ID NO:2.

63. (Withdrawn) The method of claim 17 wherein the antibody binds to a peptide fragment of Collagen XIII, the peptide fragment having SEQ ID NO:2.

64. (Withdrawn) The method of claim 23 wherein the antibody binds to a peptide fragment of Collagen XIII, the peptide fragment having SEQ ID NO:2.

65. (Withdrawn) The method of claim 43 wherein the antibody binds to a peptide fragment of Collagen XIII, the peptide fragment having SEQ ID NO:2.

66. (Withdrawn) The method of claim 44 wherein the antibody binds to a peptide fragment of Collagen XIII, the peptide fragment having SEQ ID NO:2.

67. (New) The method of claim 7 wherein the antibody reduces the rate of efflux of $\alpha 1\beta 1$ integrin positive monocytes into the interstitial space at the site of inflammation.

68. (New) The method of claim 13 wherein the antibody reduces the rate of efflux of $\alpha 1\beta 1$ integrin positive monocytes into the interstitial space at the site of inflammation.

69. (New) The method of claim 17 wherein the antibody reduces the rate of efflux of $\alpha 1\beta 1$ integrin positive monocytes into the interstitial space at the site of inflammation.

70. (New) The method of claim 23 wherein the antibody reduces the rate of efflux of $\alpha 1\beta 1$ integrin positive monocytes into the interstitial space at the site of inflammation.

Serial No.: 10/698,121

Confirmation No.: 8958

Filed: October 31, 2003

For: INDUCIBLE LIGAND FOR $\alpha 1\beta 1$ INTEGRIN AND USES

71. (New) The method of claim 44 wherein the antibody reduces the rate of efflux of $\alpha 1\beta 1$ integrin positive monocytes into the interstitial space at the site of inflammation.